Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DDI199
- Development stage
- Preclinical
- Lead developer
- ProbeChem
- Modality
- Small Molecules
- Administration
- Intraperitoneal (preclinical)
01
Overview
DDI199 is a small molecule inhibitor with activity against histone deacetylases (HDAC), cholinesterase (ChE), and monoamine oxidase (MAO). It has been shown to deregulate pathways related to the cell cycle and neurotransmission in glioblastoma stem cells (GSCs). In preclinical studies, administration of DDI199 reduced glioblastoma multiforme tumor growth. The compound is primarily used as a research tool for studying epigenetic regulation, neurotransmitter metabolism, and cancer biology[1].
02
Targets
HDAC (HDAC family)AcetylcholinesteraseMAOA (Monoamine oxidase A)
Beyond the preview
Go deeper on DDI199.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DDI199.